Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

Efforts at treating radiation-induced cognitive and neuropsychiatric declines with
medications have shown only minimal preliminary cognitive benefit and do not affect quality
of life (QOL). Given the structural and functional brain alterations associated with WBRT,
preventing rather than treating these radiation-induced changes may produce more favorable
outcomes. Innovative radiotherapy techniques can limit the dose of radiation applied to
specific brain structures without compromising tumor coverage. In this light, Radiation
Therapy Oncology Group (RTOG) recently published a study evaluating the hippocampal avoidance
whole brain radiation therapy (WBRT) in patients with brain metastases. They suggest
potential preservation of cognitive function with this approach with no perceived detriment
in survival. This concept is currently undergoing investigation in a definitive randomized
controlled study (NRG-CC003) in patients receiving prophylactic cranial irradiation for small
cell lung cancer. However, no other studies to date have prospectively evaluated avoidance of
other particularly sensitive brain regions.

One brain region that has received little attention in the radiotherapy literature is the
corpus callosum. The genu of the corpus callosum contains thin, densely packed neural fibers
that primarily connect the prefrontal association areas and the anterior inferior parietal
regions of the brain. Damage or thinning of the genu is associated with reduced functioning
on tests of executive functioning, attention, working memory, processing speed, verbal
fluency and memory in a variety of healthy and patient groups including aging, cerebral small
vessel disease, traumatic brain injury, multiple sclerosis , human immunodeficiency virus,
mild cognitive impairment secondary to Parkinson's disease, and euthymic bipolar disorder.
The limited existing data in adults receiving WBRT for brain metastases suggest that they
also perceive progressive declines in motivation following treatment. Given its apparent
involvement in a wide range of cognitive processes, the genu of the corpus callosum is an
excellent candidate for sparing in WBRT. This relatively small area has the potential to
preserve cognitive functioning across several domains if guarded from the damaging effects of
radiation. In this study patients will receive the standard whole brain radiation dose of
3000 centigray (cGy) in 10 fractions, but intensity modulated radiation therapy will be
utilized to limit radiation dose to the genu of the corpus callosum. Patients will undergo
cognitive testing at baseline and at 4-, 6- and 12-months following completion of brain
radiation to evaluate the study hypothesis.

Inclusion Criteria:

- Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be
obtained from either the primary or any metastatic site

- Mini Mental State Examination (MMSE) ≥24

- Age≥ 18 years

- Karnofsky Performance Status (KPS) ≥70

- Patient does not have metastases to the genu

- Patient must be scheduled to undergo treatment with whole brain radiation therapy
(WBRT) to manage the brain metastases

- Patients of childbearing potential (male or female) must practice adequate
contraception due to possible harmful effects of radiation therapy on an unborn child

- Patient must have the ability to understand and the willingness to sign a written
informed consent document

- All patients must be informed of the investigational nature of this study and must be
given written informed consent in accordance with institutional and federal guidelines

- Patient must have a minimal life expectancy of at least 6 months

- Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are
eligible

Exclusion Criteria:

- Prior WBRT

- MMSE<24

- Patient has brain metastases in the genu

- Patients must not have a serious medical or psychiatric illness that would, in the
opinion of the treating physician prevent informed consent or completion of protocol
treatment, and/or follow-up visits.

- KPS<70

- Non-native English speakers will be excluded since patients often lose their faculty
with the language they acquired second before their native language is affected in the
context of cognitive decline. This could adversely affect performance on verbal
cognitive tasks.

- Patients with absolute contraindication to MRI imaging are not eligible for the study